A combined medication (of which levodopa is the agent that primarily targets the brain) used to treat idiopathic parkinson’s disease. The combination allows greater amounts of levodopa to reach the brain, where it is converted to dopamine, resulting in increased dopamine levels, specifically in the dopaminergic neurons of the nigrostriatal pathway. Marketed under the brand name sinemet.
An anti-Parkinson drug combination. Levodopa and carbidopa are usually given in combination (Sinemet, Atamet) to treat Parkinson disease. Levodopa is the active ingredient that is converted into dopamine, which is a neurotransmitter in the brain. Increased amounts of dopamine in the brain relieve the symptoms of Parkinson disease. Levodopa is used to treat the stiffness, tremors, spasms, and poor muscle control associated with Parkinson disease.